Fluidigm Corp
F:FLB
Fluidigm Corp
Research & Development
Fluidigm Corp
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fluidigm Corp
F:FLB
|
Research & Development
-$38m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Research & Development
-$1.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Danaher Corp
NYSE:DHR
|
Research & Development
-$1.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-6%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Research & Development
-$196.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-5%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Research & Development
-$450m
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-3%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Fluidigm Corp
Glance View
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
See Also
What is Fluidigm Corp's Research & Development?
Research & Development
-38m
USD
Based on the financial report for Sep 30, 2025, Fluidigm Corp's Research & Development amounts to -38m USD.
What is Fluidigm Corp's Research & Development growth rate?
Research & Development CAGR 10Y
1%
Over the last year, the Research & Development growth was 31%. The average annual Research & Development growth rates for Fluidigm Corp have been -3% over the past three years , -2% over the past five years , and 1% over the past ten years .
